Outpatient Prescription Cannabinoid Utilisation in the USA: a Population-Based Study.

Alexandra Sideris,Haoyan Zhong,Jiabin Liu,Jashvant Poeran,Stavros G. Memtsoudis
DOI: https://doi.org/10.1016/j.bja.2022.11.018
IF: 11.719
2023-01-01
British Journal of Anaesthesia
Abstract:Editor—Access to cannabis for medical and recreational purposes continues to expand in the USA, and reported use has increased.1,2 Whilst the type of cannabis available to consumers largely depends on the jurisdiction in which they reside,3 patients across the country have access to four US Food and Drug Administration (FDA)-approved cannabinoid medications that are taken orally with a prescription from a provider.4 Two of these medications, dronabinol (capsule or solution) and nabilone, are synthetic versions or derivatives of delta-9-tetrahydronabinol (THC) approved for the treatment of nausea and vomiting attributable to chemotherapy or cachexia associated with AIDS.
What problem does this paper attempt to address?